SCHEMBL3016103

SCHEMBL3016103

Cc1cc(C)c(C)c(S(=O)(=O)N2CCN(c3nc(-c4ccc(Cl)cc4)cs3)CC2)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.56
LMNA P02545 6/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
MAPK1 P28482 5/20 0.56
ALDH1A1 P00352 4/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
NPSR1 Q6W5P4 2/20 0.54
TSHR P16473 1/20 0.54
MEN1 O00255 7/20 0.53
KMT2A Q03164 7/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
HTT P42858 3/20 0.46
GAA P10253 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 1/20 0.46
POLB P06746 1/20 0.46
ALOX12 P18054 1/20 0.46
BLM P54132 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3649563 0.93 POLB (0.53) MAPTLMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL3019906 0.91 SMN1; SMN2 (0.57) MAPTLMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL3014444 0.91 AR (0.57) MAPTLMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL3017914 0.90 SMN1; SMN2 (0.48) MAPTLMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL3011762 0.90 SMN1; SMN2 (0.54) MAPTLMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL3015440 0.89 MAPT (0.56) MAPTLMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL3010469 0.89 MAPK1 (0.67) MAPTLMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL3011184 0.88 SMN1; SMN2 (0.54) MAPTLMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL3019011 0.88 SMN1; SMN2 (0.54) MAPTLMNASMN1; SMN2MAPK1ALDH1A1
SCHEMBL3019081 0.88 SMN1; SMN2 (0.56) MAPTLMNASMN1; SMN2MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.